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Abstract
Background and Objectives Dasotraline is a novel inhibitor
of dopamine and norepinephrine reuptake currently being
investigated in clinical studies for the treatment of attention-
deficit/hyperactivity disorder (ADHD). Uniquely, relative to
current ADHD medications, dasotraline has a slow absorption
and long elimination half-life. Here we relate the pharma-
cokinetics and pharmacodynamics of dasotraline to reduction
inADHDsymptomsbasedon simulatedclinical trial outcomes.
Methods Dasotraline pharmacokinetics were analyzed by
population pharmacokinetic methodologies using data col-
lected from 395 subjects after single or multiple oral dose
administrations ranging from 0.2 to 36 mg (three phase I
studies and one phase II ADHD study). Population pharma-
cokinetic and pharmacodynamic models related individual
dasotraline exposures to norepinephrine metabolite 3,4-di-
hydroxyphenylglycol (DHPG) concentrations, ADHD
symptoms, and study discontinuation (probability of dropout).
Results Dasotraline pharmacokinetics were described by
a one-compartment model with dual (linear plus nonlinear)
elimination. In an ADHD population treated with daso-
traline 4 or 8 mg/day, dasotraline was characterized by a
mean apparent half-life of 47 h and plasma concentrations
reached steady-state by 10 days of dosing. A population
pharmacokinetic and pharmacodynamic model of DHPG
indicated clinically significant norepinephrine transporter
inhibition was achieved as a function of time-matched
dasotraline concentrations. Dasotraline exposure reduced
ADHD symptoms in a sigmoid Emax time-course model.
Clinical trial simulations described the effects of dose,
duration, and sample size on clinical outcomes.
Conclusion These results related dasotraline pharmacoki-
netics to pharmacological activity in ADHD, and support the
novel concept that maintaining constant, steady-state dopa-
mine and norepinephrine reuptake inhibition throughout a
24-h dosing interval is a novel pharmacological approach to
the management of ADHD symptoms.
Clinicaltrials.gov identifier: NCT01692782.
Key Points
Dasotraline has a pharmacokinetic profile of slow
absorption/elimination which provides relatively
stable plasma concentrations over a 24-h daily
dosing interval.
Dasotraline pharmacokinetics were analyzed by
population pharmacokinetic methodologies using
data collected from phase I and phase II clinical
studies.
Population pharmacodynamic models related
individual dasotraline exposures to concentrations of
the norepinephrine metabolite DHPG, ADHD
symptoms, and study discontinuation (probability of
dropout), and Monte Carlo simulations described the
effects of dose, duration, and sample size on clinical
outcomes.
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1 Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neurode-
velopmental disorder characterizedby symptomsof inattention,
hyperactivity, and impulsivity associated with clinically sig-
nificant impairment in functioning. Dopamine and nore-
pinephrine are associated with the pathophysiology of ADHD,
and drugs that facilitate synaptic concentrations of dopamine
and norepinephrine are clinically useful in the pharmacological
management of ADHD symptoms [1]. Dasotraline [(1R,4S)-4-
(3,4-Dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine]
is a novel compound in clinical development for the treatment
of ADHD. Dasotraline is a potent inhibitor of human dopa-
mine transporters (DAT; dopamine uptake IC50 3 nM) and
norepinephrine transporters (NET; norepinephrine uptake
IC50 4 nM), and a weaker inhibitor of human serotonin
transporters (SERT; serotonin uptake IC50 15 nM; Sunovion
data on file). The dasotraline pharmacokinetic profile of slow
absorption/elimination is unique among current stimulant and
nonstimulant medications indicated for ADHD, and can
support relatively stable plasma concentrations over a 24-h
daily dosing interval. A phase II clinical trial (NCT01692782)
with dasotraline demonstrated statistically and clinically
meaningful effects in adults with ADHD [2].
Pharmacokinetic and pharmacodynamic modeling provides
a method for synthesizing data from a variety of sources,
including receptor occupancy, clinical pharmacology, efficacy
measures, and safety outcomes for newdrugs. Pharmacokinetic
and pharmacodynamic models can then be used to perform
Monte Carlo simulations of clinical trial outcomes under vari-
ous treatment scenarios. Simulations provide quantitative
assessments of drug performance under different clinical trial
scenarios, and a basis for deciding whether to proceed with
subsequent late-stage clinical development [3–5].
This paper describes the development of pharmacokinetic
and pharmacodynamic models of dasotraline in ADHD and
the subsequent clinical trial simulations that were performed
to assess dose and exposure-response relationships. The data
used in the development of these models included the
pharmacokinetics of dasotraline following single- and mul-
tiple-dose administration, the effect of dasotraline on NET
inhibition, and the relationship between dasotraline exposure
and efficacy and safety outcomes from a phase II trial in
adults with ADHD. The results of the simulations were used
to inform the design of subsequent phase III efficacy studies.
2 Methods
Dasotraline doseswere administered orally either as a solution
or as an oral capsule formulation, with equivalent systemic
exposure between dosage forms. Dasotraline concentrations
in human plasma were determined using a validated enan-
tioselective liquid chromatography-tandem mass spectrome-
try (LC–MS/MS) method with a lower limit of quantitation
(LOQ) of 10 pg/ml. Levels ofDHPGwere determined using a
validated LC–MS/MS method with an LOQ of 200 pg/ml. A
detailed summary of analytical methods is provided in
Appendix A (see online Supplementary Material).
In Study 001, single doses of placebo or dasotraline, as an
oral solution ranging from 0.2 to 36 mg, were administered
to 171 healthy adult volunteers (total 128 subjects in daso-
traline analysis, 13 cohorts) to assess the single-dose phar-
macokinetics in a single-ascending dose design. In Study
002, 36 healthy adult volunteers (total 27 subjects in daso-
traline analysis, three cohorts) were randomized to receive
placebo or 1, 2, or 3 mg/day of dasotraline oral solution for
21 days in a multiple ascending dose design. Study 011
evaluated the pharmacokinetics of single doses of placebo or
dasotraline (8, 12, or 16 mg oral solution) in 29 healthy adult
volunteers and dasotraline plasma concentrations were
measured at 23, 24, and 26 h post dose (total of 19 subjects in
dasotraline analysis) in a positron emission tomography
(PET) study [6]. In a phase II clinical trial (Study 201), 341
adult outpatients meeting DSM-IV-TR criteria for ADHD
were randomized to 4 weeks of double-blind, once-daily
treatment with dasotraline 4, 8 mg/day, or placebo [2]. The
primary efficacy endpoint was change from baseline at week
4 in the ADHDRating Scale, Version IV, with adult prompts
(ADHDRS-IV) total score. In Study 201, dasotraline plasma
concentrations and DHPG plasma levels were collected
weekly. A total of 221 subjects were included in the analysis
of dasotraline concentrations from Study 201.
All of the studies included in the current pharmacokinetic
and pharmacodynamic analyses were approved by an insti-
tutional review board at each investigational site and each
study was conducted in accordance with the International
Conference on Harmonisation Good Clinical Practice
Guidelines and with the ethical principles of the Declaration
of Helsinki. Prior to study entry, all patients reviewed and
signed an informed consent document explaining study
procedures and potential risks. Study 201 implemented an
independent data and safety monitoring board to review and
monitor patient safety data throughout the study.
Nonlinear mixed effects models were used to describe
the relationship of the pharmacokinetic and pharmacody-
namic behavior of dasotraline, DHPG concentrations, and
the primary outcome measure, the total score on the ADHD
Rating Scale, Version IV (ADHD RS-IV). Time to study
dropout was analyzed using a semi-parametric Cox pro-
portional hazard model relating dasotraline average con-
centration (Cav) and the interaction between Cav and time
to the log of the survival function for dropout. The final
models for DHPG concentrations, ADHD RS-IV total
scores, and dropout were validated using simulations and
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visual-predictive checks to assess concordance between the
model-based simulated data and the observed data. For
combined data from the phase I and phase II studies,
noncompartmental analyses were performed using
Phoenix WinNonLin (Version 6.2). Population model-
ing and simulations were performed using NONMEM,
Version 7.1.2.1. Efficacy analysis of simulated clinical
trials, and survival analysis of time to study dropout were
performed using SAS Version 9.2. Gaussian distributions
were fit using GraphPad Prism (Version 6.03, GraphPad
Software, Inc.). As an individual measure of dasotraline
exposure, Cav was calculated by numerical integration
using the developed population pharmacokinetic model for
dasotraline and the associated individual-specific parame-
ter estimates using NONMEM.
The dasotraline population pharmacokinetic model was
developed on the basis of a 4570 dasotraline concentrations
measured from a total of 395 subjects. Population modeling
of DHPG concentrations was conducted on the basis of 759
DHPG measurements from a total of 220 subjects. Popu-
lation modeling of ADHD RS-IV Scores was conducted on
the basis of 1,847 observations from a total of 330 subjects
in ADHD Study 201.
Statistically significant predictors of pharmacodynamic
variability for DHPG concentrations and ADHD RS–IV
scores were identified through a combination of graphical
inspection and univariate forward selection (a = 0.05),
followed by backward elimination (a = 0.001) of stationary
covariates (age, race, sex, baseline weight, baseline body
mass index, ethnicity, baseline DHPG, baseline ADHD RS-
IV total scores, and baseline insomnia severity as measured
by the Insomnia Severity Index [7]). Statistically significant
predictors of the time to study dropout were identified using
forward selection (a = 0.01) of the stationary covariates
(age, baseline weight, baseline body mass index (BMI),
baseline ADHDRS-IV total score, baseline DHPG, baseline
heart rate, baseline insomnia severity index, sex, race, and
ethnicity). Insomnia severity index values collected at mul-
tiple times throughout the study were also evaluated as a
time-varying covariate on time to study dropout.
Clinical trial simulations (Monte Carlo) used exposure-
response relationships for dasotraline (DHPG and ADHD
RS-IV total scores) and subject dropout to determine
likelihoods of positive trial outcomes (defined as statisti-
cally significant ADHD RS-IV response following daso-
traline treatment compared to placebo). All virtual subjects
that completed each study were assumed to have main-
tained the target dose level for each simulated dosing
regimen scenario. To generate virtual subjects, values of
the model predicted significant covariates for the pharma-
cokinetic and exposure-response models were assigned by
randomly resampling these characteristics from subjects in
the phase II clinical trial [2]. The Cox proportional hazard
model for dropout was applied to the simulated data for the
first 28 days of treatment to obtain a probability of dropout
for each subject at each week that was time and concen-
tration dependent as in Study 201. This model-predicted
probability was compared to a uniform random number to
select subjects to be discontinued from the simulations on
each week.
The change from baseline in simulated ADHDRS-IV total
score at each week was analyzed with a mixed effect model
with repeated measures (MMRM), identical to the primary
analysis in Study 201. Fixed effects included treatment, visit,
visit-by-treatment interaction, and baseline ADHD RS-IV
total score. A pairwise comparison (least squares mean dif-
ferences, LS mean) of each treatment group against placebo
was performed; a simulated trial’s treatment arm was con-
sidered successful if the LS mean difference achieved statis-
tical significance over placebo (P\ 0.05). The percentage of
clinical trials with a statistically significant difference in
ADHD RS-IV total scores between placebo and dasotraline
treatment arms on week 4 was summarized as the probability
of success for that design scenario.
3 Results
3.1 Single-Dose and Multiple-Dose
Pharmacokinetics
The pharmacokinetics of dasotraline were evaluated in a
single-dose study in 128 healthy subjects (63 male, 65
female). Subjects had mean (±SD) body weights of
72 ± 13 kg. Dasotraline was slowly absorbed into systemic
circulation, reaching maximum concentrations (Tmax) at
approximately 10–12 h post-dose (Fig. 1). Over the dose
range of 0.2 to 36 mg, peak mean plasma concentrations
ranged from 0.08 to 15.5 ng/ml. Dose-dependent increases in
exposure were nearly dose-proportional, where a 4-fold
higher dose resulted in 4.2-fold and 5.6-fold increases in
maximum plasma concentration (Cmax) and area under the
concentration–time curve (AUC), respectively (Fig. 2).
Exposure values exhibited lowvariability (20 %coefficient of
variation (CV) based on Cmax, 60 % CV based on AUC;
(Fig. 2) across individuals over the dose range. Elimination of
dasotraline was slow with mean half-life (t) values among
the dose cohorts ranging from 47 to 77 h. Following multiple
daily doses, dasotraline exposure (based on ratios of Cmax or
AUC) accumulated 8- to 11-fold over 21 days (Fig. 1).
3.2 Population Pharmacokinetic
and Pharmacodynamic Models
Dasotraline pharmacokinetics were modeled as a one-com-
partment model with sequential zero-order followed by first-
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order absorption and dual (nonlinear and linear) elimination.
The model component of nonlinear apparent clearance rep-
resented a saturable elimination pathway operating at
approximately 50 % of its capacity at lower dasotraline
concentrationswith an estimatedMichaelis–Menten constant
(Km) of around 1.7 ng/ml. As dasotraline concentrations
Fig. 1 Dasotraline pharmacokinetics in healthy adults. Mean daso-
traline concentrations (ng/ml plasma) are presented on a logarithmic
scale for the first 24 h (left panel), the remaining 28 days (middle
panel) following single doses from 0.2 to 36 mg, N = 9 subjects
(N = 8 for 0.5 mg), and following multiple daily doses (right panel)
for 21 days followed by a 7-day washout (N = 9, 8, 7 for 1, 2,
3 mg/day, respectively). Plasma lower limit of quantification (LOQ)
for dasotraline was 10 pg/ml; values below the LOQ were set to LOQ
divided by 2. t half-life, Tmax time to Cmax, Cmax maximum plasma
concentration
Fig. 2 Dose-proportionality of dasotraline. A linear equation
(±90 % prediction bands) was fit to the relationship between
exposure measures [maximum plasma concentration (Cmax), area
under the concentration–time curve (AUC)] and dose, each on a log
base 2 scale to show fold-changes in dose and exposure values. Fitted
slope parameters for Cmax and AUC were 1.1 and 1.4, respectively,
each having lower 95 % confidence values greater than 1. Residuals
between fitted and observed linear dose-exposure relationships are
shown below by dose level. The distribution of residuals across all
dose levels are shown in histograms with fitted Gaussian distributions.
The Gaussian standard deviation of Cmax was 0.25 units or 1.2-fold,
yielding an overall estimate of 20 % CV. The Gaussian standard
deviation of AUC was 0.70 units or 1.6-fold (60 % CV). CV
coefficient of variation
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increased above 3 ng/ml, the nonlinear component con-
tributed less to total elimination such that, in the therapeutic
range of concentrations ([6 ng/ml), dasotraline exposure and
pharmacokinetics were linear. The functional form of the
dasotraline population pharmacokinetic model and final
parameter estimates are described in Appendix B (see online
Supplementary Material). Covariate analysis failed to iden-
tify age, total bilirubin, alanine aminotransferase (ALT), sex,
race, or ethnicity as significant predictors of variability in the
population pharmacokinetic model (a = 0.05, forward
addition; a = 0.001, backward elimination). However, body
weight (kg) was a significant covariate for dasotraline expo-
sure andwas therefore included in themodel. Goodness-of-fit
plots (Fig. 3) indicated a good fit of individual predicted
concentrations versus observations andwith limited bias. The
population distributions of concentrations measured at
3 weeks of daily dosing had a mean of 6.6 and 18 ng/ml for
the 4 and 8 mg/day dose levels, respectively (top panels
Fig. 3). The variability across the population was character-
ized by the standard deviations of 1.7-fold and 2.0-fold for the
Gaussian distributions of dasotraline concentration for 4 and
8 mg/day dose levels, respectively (Fig. 3). The dasotraline
concentrations over time observed in adults with ADHD in
Study 201 [2] matched well with the final population phar-
macokinetic model predictions over time for dasotraline
(Fig. 4a).
Population pharmacokinetic model parameter estimates for
each individual patient in the phase II clinical trial in ADHD
were utilized to simulate 4 weeks of daily doses of either 4 or
8 mg/day, followed by 4 weeks of washout. Simulated wash-
outs were used to fit noncompartmental pharmacokinetic
parameters for each subject. The distribution of (natural log)
half-life values across the population of individuals included in
the phase II clinical trial was normally distributed with a fitted
Gaussian mean half-life of 47 h (Fig. 5). Noncompartmental
pharmacokinetic parameters of apparent clearance and volume
of distribution were also normally distributed across the pop-
ulation with fitted Gaussian parameters mean (l) and standard
deviation (r) of l = 26 L/h (l - r = 14, l ? r = 46) for
apparent clearance, and l = 1652 L (l - r = 1036,
l ? r = 2635) for volume of distribution.
Dasotraline plasma concentrations were associated with
decreases in plasma concentrations of the norepinephrine
metabolite DHPG. In order to estimate the extent and onset
of NET inhibition by dasotraline, a population pharma-
cokinetic and pharmacodynamic model was developed to
describe the relationship between clinically relevant daso-
traline exposures. TheDHPGmodel equations and estimated
parameters are summarized in Appendix C (see online
Supplementary Material). The observed values for DHPG in
the phase II clinical trial matched well with model predic-
tions for DHPG changes (Fig. 4b). Covariate analysis failed
to identify age, baseline weight, baseline BMI, baseline
DHPG, gender, race, or ethnicity as predictors of variability
in the parameters of the DHPG model (a = 0.05, forward
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3.3 Population Modeling of ADHD RS-IV Scores
ADHD symptom reductions in the phase II clinical trial
were modeled as a function of dasotraline exposure. The
functional form and parameter estimates are described in
Appendix D (see online Supplementary Material). The
typical value of baseline ADHD RS-IV total score was
estimated at 36.8. The Emax, which represents the maxi-
mum possible reduction in ADHD RS-IV total score from
baseline due to time alone was estimated at 10.2. The
population mean estimates for the time producing 50 % of
Emax (T50) were 0.762 weeks for placebo and 1.08 weeks
for the dasotraline treatment arms, respectively. Although
the influence of age, baseline weight, baseline BMI,
baseline ADHD RS-IV total score, baseline DHPG, base-
line insomnia severity index, sex, race, and ethnicity was
evaluated in the model, none of the covariates was found to
be a statistically significant predictor of variability in
ADHD RS-IV total score (a = 0.05, forward addition;
a = 0.001, backward elimination). The model-predicted
ADHD RS-IV total scores corresponded well with the
observed values (Fig. 4c, d). The population model iden-
tified an exposure-response relationship between dasotra-
line concentrations and improvements in ADHD symptoms
(Fig. 4e). The population pharmacokinetic/ADHD model
was adequate for simulating clinical trial outcomes.
3.4 Time to Study Dropout
In ADHD Study 201, 9 % of placebo subjects and 15 and
45 % of subjects administered 4 and 8 mg/day dropped out
of the study, respectively. Time to dropouts was modeled
using a Cox proportional hazard survival model. The time
to discontinuation (dropout) was modeled as a function of
dasotraline exposure (Cav). An interaction term between
time to study dropout and dasotraline exposure was
incorporated to account for the nonproportional effects of
the interaction between both dasotraline exposures and
time on the log of the survival function. The model-
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Fig. 4 Population pharmacokinetic (PK) and pharmacodynamic (PD)
models of dasotraline. Dasotraline concentrations observed in the
phase II clinical trial in attention deficit/hyperactivity disorder
(ADHD) (symbols mean ± 95 % CI; a) compared to population PK
model predicted mean concentrations (lines). Norepinephrine metabo-
lite 3,4-dihydroxyphenylglycol (DHPG) concentrations (pg/ml
plasma) observed in the phase II clinical trial (symbols mean ± 95 %
CI; b) compared to population PK and PD model predictions (lines).
Reductions in ADHD symptoms observed in the phase II clinical trial
(symbols are least square mean differences from placebo ± 95 % CI;
c and d) compared to population PK and PD model predictions
(lines). Mean dasotraline concentrations (Cav) were linearly related to
ADHD symptom reductions in a sigmoid Emax time-course PK and
PD model for individual subjects in the phase II clinical trial (e)
Fig. 5 Distribution of half-life values. Individual subjects in the
phase II clinical trial of dasotraline were simulated using the
established population pharmacokinetic (PK) model to estimate the
PK of dasotraline washout following 4 weeks of daily dosing. The
population distribution of (natural log) half-life values was normally
distributed and described by Gaussian-fitted values of mean (l) and
standard deviation (r) of l = 47 h (l - r = 38, l ? r = 59)
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predicted risk of study dropout increased with increasing
average dasotraline concentrations (hazard ratio of 1.24,
95 % CI 1.12–1.36). The interaction term between daso-
traline exposure and time was estimated to be -0.0063
(42.7 % SEM), indicating an increase in study dropout as
time increases. The risk of study dropout was reduced by
approximately eightfold when comparing the hazard ratio
for 8 versus 4 mg/day, assuming the median Cav for each
dose. Model-predicted values indicated no apparent bias
and illustrated good concordance between the model-based
simulations and the observed data estimates of survival for
each dose and corresponding range of Cav values observed
throughout the study (Fig. 6). Although the influence of
age, baseline weight, baseline BMI, baseline ADHD RS-IV
total score, baseline DHPG, baseline heart rate, Insomnia
Severity Index (baseline and time varying), sex, race, and
ethnicity was evaluated in the survival model, none of the
covariates were found to be a statistically significant pre-
dictor of variability in the dropout rate (a = 0.01 for for-
ward selection).
3.5 Clinical Trial Simulations
Clinical trial simulations (Monte Carlo) were performed to
predict the minimal effective dose, the no-effect dose, and
the effect sizes expected for longer durations of treatment.
Figure 7 summarizes the statistical outcomes (fraction of
trials with P\ 0.05 for a dasotraline comparison against
placebo) of N = 500 simulated clinical trials as a function
of dose, duration, and sample size. The effects of time- and
concentration-dependent dropouts were applied in the
simulations, with a relatively small impact on the proba-
bilities of success. There was at most only a 3 % reduction
in the probability of success for simulations conducted
under the influence of dropout compared to simulations
where all subjects completed the treatment period (no
dropout).
The average effect size at 4 weeks for the 4 mg/day
treatment group in simulated clinical trials was
0.25 ± 0.11 standard deviation (SD), matching the week 4
effect size observed in the phase II clinical trial for
Fig. 6 Time to study dropout.
Simulated percentiles of
subjects who dropped out of the
study versus days with Kaplan–
Meier estimates of the observed
data by dasotraline dose
a b c
Fig. 7 Clinical trial simulations with dasotraline in adults with
attention deficit/hyperactivity disorder (ADHD). The probability of a
trial with statistically significant separation of treatment arms from
placebo arm was estimated using Monte Carlo simulations of 500
clinical trials as a function of trial duration (a), dose (b), and sample
size (c)
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4 mg/day [2]. The simulations predicted further increases
in effect sizes for trial durations beyond 4 weeks (Fig. 7a);
at 8 weeks of treatment, 4 mg/day mean effect size was
0.31 ± 0.11 SD. As a result, the probability of success of a
4 mg/day treatment was above 80 % by 8 weeks of treat-
ment with 200 subjects per arm (Fig. 7b). Therefore, sim-
ulations predicted 4 mg/day as the minimum effective
dose.
The probability of success for the 4 mg/day dose level at
week 8 was below 80 % for sample sizes of 150 per arm.
The sample size of 200 subjects per arm improved the
probability of success at week 8 to above 80 % for the
4 mg/day doses. At the 2 mg/day dose level, however,
further increasing sample size to 300 per arm was still
insufficient to demonstrate positive efficacy, thus predict-
ing 2 mg/day as the no-effect dose (Fig. 7c). Increasing the
length of the clinical trials from 8 to 12 weeks resulted in
only a small increase in the percentage of successful trials,
thus predicting an optimal trial duration of 8 weeks.
These clinical trial simulations, based on an under-
standing of the exposure-response relationship for daso-
traline in adults with ADHD, supported further
investigation of dasotraline in adults with ADHD in a
phase III clinical trial of 8 weeks of treatment, doses of 4
or 6 mg/day, and sample size of 200 subjects per group
(NCT02276209).
4 Discussion
Pharmacokinetic and pharmacodynamic modeling and
simulation were used to integrate the data on dasotraline
pharmacology and phase II clinical trial outcomes to
inform the design of subsequent clinical trials. The phar-
macokinetic and pharmacodynamic model developed from
the available data described correlations between dasotra-
line exposure and various pharmacodynamic outcomes,
including: (a) the reduction in ADHD symptoms, (b) the
inhibition of norepinephrine reuptake (decreases in plasma
DHPG concentrations), (c) the time to study dropout, and
(d) outcomes of simulated clinical trials of adults with
ADHD. The pharmacokinetic and pharmacodynamic
model built on this data provided a quantitative basis for
subsequent dasotraline clinical trials.
The PKs of dasotraline in clinical study subjects was
well described by a 1-compartment pharmacokinetic model
across a range of body weights (40–130 kg), dose levels
(0.2–36 mg), and treatment durations (single dose to
28 days). The influence of body weight (kg) on dasotraline
concentrations was included in the final model. The vari-
ability of dasotraline pharmacokinetics was otherwise
independent of clinical covariates of age, sex, race, or
indicators of liver functioning. Although the elimination of
dasotraline was modeled as time- and concentration-de-
pendent with the relative contribution of nonlinear and
linear clearance pathways conditional on the magnitude,
frequency, and duration of dosing, overall the model of
dasotraline pharmacokinetics was both predictable and
nearly dose-proportional in both single-dose and multiple-
dose clinical settings. After 28 days of dosing in adults
with ADHD the population mean dasotraline t was esti-
mated to be 47 h and characterized by a relatively narrow
population distribution, indicating 10 days is an appropri-
ate clinical estimate of the five ts for washout or estab-
lishing steady-state.
Reductions in plasma concentrations of DHPG are a
clinically significant effect of NET inhibitors such as
duloxetine [8, 9], where decreases are thought to indicate
decreased uptake and neuronal metabolism of nore-
pinephrine. Dasotraline concentrations above 2 ng/ml were
associated with reductions in plasma DHPG, indicative of
central inhibition of NETs. In humans, the extent of inhi-
bition by the selective NET inhibitor atomoxetine was
estimated to be above 90 % [10], and daily administration
of atomoxetine 80 mg reduced plasma DHPG concentra-
tions by 37 % [11]. By comparison, the dasotraline popu-
lation pharmacokinetic and pharmacodynamic model of
DHPG suggested that the pharmacodynamic response of
NET inhibition (mean reductions in DHPG) had not
reached maximal levels of inhibition. Overall, the observed
values for DHPG in the phase II clinical trial [2] matched
well with model predictions for DHPG changes and were
consistent with clinically significant levels of NET inhibi-
tion by dasotraline within the first days of dosing and
sustained over 4 weeks of daily doses.
Methylphenidate, at doses used clinically to treat
ADHD, also occupies greater than 50 % of DATs [12],
together with measurable occupancy of NETs [13]. A prior
human PET study conducted following single doses of 8,
12, or 16 mg demonstrated that dasotraline plasma con-
centrations of 4.5 ng/ml were associated with 50 % DAT
occupancy, and with no significant serotonin transporter
occupancy [6]. The exposures reported here suggest that
dasotraline efficacy in ADHD is associated with greater
than 50 % inhibition of DATs. Taken together these results
suggest that dasotraline is acting as a dual dopamine and
norepinephrine reuptake inhibitor in ADHD.
Dasotraline demonstrated an exposure-response rela-
tionship for reduction in ADHD symptoms. A substantial
portion of the change from baseline occurred at the first visit
post-baseline (week 1) at a time where dasotraline concen-
trations were still relatively low compared to steady-state
levels. In fact, the LS mean ADHD RS-IV total scores at the
week 1 visit were equivalent among treatment groups and
likely related to a placebo effect [2]. Based upon population
mean parameter estimates derived from ADHD Study 201, a
144 S. C. Hopkins et al.
subject with a baseline ADHD RS-IV with adult prompts
total score of 36.8 commencing daily dasotraline treatment
for 4 weeks had an approximate total reduction in ADHD
RS-IV total score of 11 at the end of 4 weeks of treatment
(attaining an approximate score of 26) if average drug con-
centrations achieved consistent levels near 7 ng/ml for 4 mg.
Assuming a dose of 8 mg dasotraline and an average con-
centration of 16.5 ng/ml, an approximate total reduction in
ADHD RS-IV total score of 14 for the typical subject was
achieved at the end of 4 weeks of treatment (attaining an
approximate score of 23).
Dasotraline also demonstrated an exposure- and time-
dependent relationship for the rate of study discontinuation
(dropout) in the phase II clinical trial, generally increasing
probabilities for study discontinuation with increasing
dasotraline exposure, particularly early during treatment
initiation. Adverse events pharmacologically related to the
onset of NET and DAT inhibition were the most common
reason for study dropout during the double-blind period
(27.8 % of 8 mg/day group), supported by the predictions
of the pharmacokinetic and pharmacodynamic model
relating dasotraline exposure to the probability of study
dropout. Due to relatively low sample sizes, reasons for
discontinuation (by adverse event terms such as insomnia,
dry mouth, appetite, etc.) were not modeled separately
within this analysis. When examined as a function of dose,
exposure, and time in the study, insomnia itself (both
baseline level of insomnia or time-varying changes in
insomnia) was not a statistically significant predictor of
variability in the dropout rate. Based on this analysis,
random allocation to fixed doses of dasotraline, without
habitutation or a gradual dose escalation, may have con-
tributed to the observed rates of study discontinuation due
to adverse events, particularly for the 8 mg/day dose group.
Clinical trial simulations predicted clinical trial out-
comes of longer duration and different dose levels. Simu-
lations incorporating exposure-response relationships for
dasotraline pharmacodynamics (DHPG concentrations) and
efficacy (ADHD RS-IV total scores) and subject dropout
conducted over a range of doses and durations predicted:
(a) the minimal effective dose of 4 mg/day, (b) the no-
effect dose of 2 mg/day, (c) the optimal 8-week duration of
treatment, and (d) sample sizes appropriate for future
adequate and well controlled efficacy studies.
5 Conclusions
Taken together, these results describe quantitatively the
exposure-response relationships of dasotraline and its
pharmacological activity in ADHD. The pharmacokinetic
and pharmacodynamic models described here supported
the further clinical development of dasotraline in ADHD.
The novel pharmacokinetic and pharmacodynamic profile
of dasotraline in ADHD supports the concept that main-
taining constant, steady-state inhibition of both DATs and
NETs is a novel pharmacological approach to the man-
agement of ADHD symptoms.
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